RIVASTIGMINE TARTRATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rivastigmine Tartrate, and what generic alternatives are available?
Rivastigmine Tartrate is a drug marketed by Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orbion Pharms, Sun Pharm, and Watson Labs. and is included in ten NDAs.
The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rivastigmine Tartrate
A generic version of RIVASTIGMINE TARTRATE was approved as rivastigmine tartrate by SUN PHARM on October 22nd, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RIVASTIGMINE TARTRATE?
- What are the global sales for RIVASTIGMINE TARTRATE?
- What is Average Wholesale Price for RIVASTIGMINE TARTRATE?
Summary for RIVASTIGMINE TARTRATE
| US Patents: | 0 |
| Applicants: | 10 |
| NDAs: | 10 |
| Finished Product Suppliers / Packagers: | 13 |
| Raw Ingredient (Bulk) Api Vendors: | 130 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,723 |
| Drug Prices: | Drug price information for RIVASTIGMINE TARTRATE |
| DailyMed Link: | RIVASTIGMINE TARTRATE at DailyMed |
Recent Clinical Trials for RIVASTIGMINE TARTRATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duke University | Phase 1/Phase 2 |
| Taishoff Family Foundation | Phase 1/Phase 2 |
| Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Phase 1/Phase 2 |
Pharmacology for RIVASTIGMINE TARTRATE
| Drug Class | Cholinesterase Inhibitor |
| Mechanism of Action | Cholinesterase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for RIVASTIGMINE TARTRATE
Paragraph IV (Patent) Challenges for RIVASTIGMINE TARTRATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EXELON | Oral Solution | rivastigmine tartrate | 2 mg/mL | 021025 | 1 | 2004-11-05 |
| EXELON | Capsules | rivastigmine tartrate | 1.5 mg, 3 mg, 4.5 mg and 6 mg | 020823 | 3 | 2004-04-21 |
US Patents and Regulatory Information for RIVASTIGMINE TARTRATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orbion Pharms | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 090879-004 | Jun 10, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Macleods Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 203148-004 | Aug 22, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sun Pharm | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 077131-001 | Oct 22, 2007 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Orbion Pharms | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 090879-001 | Jun 10, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alembic Pharms Ltd | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 091689-001 | Jun 12, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | RIVASTIGMINE TARTRATE | rivastigmine tartrate | CAPSULE;ORAL | 207797-002 | Sep 28, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
